|
Rivaroxaban for AFib + CAD, HF is Preventable, and PFA’s Phrenic Impact
August 18, 2025
|
|
|
|
|
Together with
|
|
|
|
“Longevity without purpose is just survival. We’re optimizing everything: sleep, nutrition, biomarkers, training zones. But have we forgotten to optimize meaning?”
|
|
Howard Luks, MD
|
|
|
Cardiology Pharmaceuticals
|
|
|
|
|
|
New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups.
- Rivaroxaban (Bayer/J&J’s Xarelto) is a direct oral anticoagulant that inhibits Factor Xa, preventing blood clot formation.
- Current practice in AFib patients with CAD often combines rivaroxaban with antiplatelet therapy, but this increases bleeding risk.
The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and ≥80 years) to compare rivaroxaban monotherapy against rivaroxaban plus antiplatelet therapy over 3.5 years, and found that…
- Rivaroxaban monotherapy reduced major CV events across all age groups, with the most pronounced benefit in patients ≥80 years (6.2% vs 10.3% event rate).
- Bleeding safety advantages were highest in younger patients (<70 years), where monotherapy reduced major bleeding from 2.3% to 0.5%.
- No significant adverse effects were found across the age groups, suggesting stable benefits regardless of patient age.
These findings challenge the current paradigm of dual antithrombotic therapy in this high-risk population since the current status quo is adding antiplatelet therapy to anticoagulation.
- If validated, the results could help shift treatment guidelines to a simpler monotherapy for the estimated 2.7M Americans with both AFib and CAD.
- The results also add to growing evidence supporting anticoagulation monotherapy strategies, joining recent data from other DOAC trials, which have found monotherapy to be just as effective if not better.
The Takeaway
While only a post-hoc analysis, this study suggests that rivaroxaban monotherapy could offer consistent clinical benefits across age groups in AFib patients with stable CAD, however we’ll have to see more direct research to back up these preliminary findings.
|
|
Redefining Percutaneous Coronary Intervention
Learn about the AGENT™ Drug-Coated Balloon from Boston Scientific and how this technology is expanding the treatment options for patients with in-stent restenosis in the U.S. Rx only. (Sponsored by Boston Scientific)
|
|
GLS Analysis of Us2.ai’s Fully-Automated Software
Ten years after the first head-to-head comparison of 2D echocardiography, the latest review suggests Us2.ai is among the easiest to use and integrate. Read the study to learn about how Us2.ai’s software requires zero operator input, operates without human intervention, and leads to high agreement with traditional semi-automated speckle- tracking software solutions.
|
|
Explore Vitrea Advanced Visualization
Discover Canon Medical Healthcare IT’s suite of advanced imaging workflows designed to increase efficiency in cardiovascular imaging, and facilitate the assessment, diagnosis, and treatment of cardiovascular diseases. These cutting-edge tools support the delivery of faster, more accurate care while integrating seamlessly into clinical workflow
|
|
- Stalking Stress Hurts the Heart: Understanding stress’ impact on heart health, an AHA study suggests experiencing stalking could have significant CVD implications for women. A 20-year study of 66k women in the Nurses’ Health Study II examined links between stalking/restraining orders and cardiovascular disease risk, finding that 11.7% of participants reported stalking and 5.6% had obtained restraining orders. Women who experienced stalking had 41% increased CVD risk, while those obtaining restraining orders had 70% increased risk.
- Spironolactone Recall: The FDA recalled over 11k bottles of Spironolactone blood pressure medication (25 mg tablets) due to aluminum contamination. The affected bottles, manufactured by Frontida BioPharm and distributed by Sun Pharmaceutical, have lot number P3314 and expire November 30, 2026. The August 5 recall was classified as Class II risk, meaning potential temporary adverse effects with low probability of serious consequences.
- Heart Rate is a Central POTS Symptom: Ivabradine, a selective heart rate-lowering medication could help us better understand heart symptoms in POTS patients. Researchers examined ivabradine treatment in POTS patients and found it significantly reduced standing heart rate spikes from 40 bpm to 15 bpm without affecting blood pressure. As a result, patients’ Malmö symptom score improved significantly from 86 to 39 and strong correlation existed between heart rate reduction and symptom improvement. These results suggest tachycardia in POTS could be central to symptom pathophysiology, supporting heart rate reduction as therapeutic.
- Reprieve Raises Funds for FASTR II: Reprieve Cardiovascular closed an oversubscribed $61M Series B financing to advance its intelligent decongestion management therapy for acute decompensated heart failure. The funding is earmarked for the global FASTR II pivotal trial which will evaluate the Reprieve system against optimal diuretic therapy, supporting its future FDA premarket approval submission.
- CCC + CAC Predicts Cardiovascular Woes: More evidence is coming in on the utility of CT-derived measures of costal cartilage calcium for predicting cardiovascular problems. In a paper in European Radiology, researchers added CCC measurements to conventional coronary artery calcium scores in people with diabetes. Among 1.4k people, adding CCC to CAC improved predictive power in older diabetics (C-index: 0.69 vs. 0.66), but had no effect in non-diabetics. CCC could be a sign of broader systemic non-cardiovascular calcification.
- GLP-1s Are Coming to Medicare: Medicare and Medicaid are apparently gearing up to cover GLP-1s, a potentially huge victory for patients and drugmakers. GLP-1s can run ~$1,000 per month without coverage, but The Washington Post reported that the Trump administration plans to pilot covering the costly drugs for obesity starting in 2026 for Medicaid and 2027 for Medicare. If that plan ultimately takes shape, it would be great news for expanding access to GLP-1s beyond diabetics, which also makes it great news for Novo and Lilly.
- HFSA and ASPC Reframe HF: A joint scientific statement from the Heart Failure Society of America and American Society for Preventive Cardiology reframes heart failure as preventable rather than inevitable. Published in several journals, it establishes the first national framework linking prevention with heart failure management across all disease stages. The approach emphasizes early risk identification, multidisciplinary care, and innovative tools like biomarkers and AI models.
- Aortic Leaflets, QAV vs. BAV: The shape of your aortic valve leaflets could impact your heart health. A recent cohort study compared 139 quadricuspid aortic valve (QAV) patients matched 1:5 to 695 bicuspid aortic valve (BAV) patients and found that the groups had similar high rates of aortic valve intervention (77.4% vs 75.7%). However, QAV patients had increased heart failure hospitalization risk (AHR: 2.52) and more cardiomyopathies, while BAV patients had higher rates of infective endocarditis (9.6% vs 0%) and aortic surgery (33.8% vs 5.1%).
- i-CARE for CAD: A randomized controlled trial of CAD patients in Hong Kong suggests “i-CARE,” a smartphone-based self-care intervention could have an impact on quality of life. Researchers randomized 249 patients and found that compared to standard care, i-CARE significantly improved self-care maintenance and confidence at 3 and 6 months. Some secondary benefits also included reduced systolic and diastolic blood pressure and improved health-related quality of life, with some effects persisting to 6 months.
- PFA Damages the Phrenic Nerve: Although exceptionally effective at treating AFib, new research suggests pulsed field ablation could impact the phrenic nerve in the heart. Researchers studied 64 patients undergoing pulsed field ablation for atrial fibrillation and found that phrenic nerve injury occurred in 40.6% of cases during the procedure, with 18.8% showing incomplete recovery by procedure end. While most patients recovered, one showed persistent dysfunction at three months, challenging the assumption that PFA’s myocardial selectivity prevents phrenic nerve complications.
- Cardiology’s Latest NTAPs: The last several weeks saw several cardiotech companies notch financial wins thanks to the CMS’ New Technology Add-on Payment (NTAP) program. As part of the program, Abbott’s Esprit BTK System, Renata’s Minima stent, EBR’s WiSE CRT System, and Pi-Cardia’s ShortCut leaflet modification device will be eligible for additional Medicare reimbursement with inpatient use. CMS offers NTAP status to companies with substantial clinical improvement over existing technologies to help offset adoption costs and collect cost data to inform future reimbursement rates.
|
|
The Benefits of Outsourced Post-Processing
Using an outsourced cardiac image post-processing solution doesn’t have to mean sacrificing control of the results. Discover how PIA’s customizable post-processing workflow can help you get the most out of your images.
|
|
Identify and Treat Cardiovascular Disease
Complex care pathways make getting patients to the next step a challenge. See how Tempus Next, an AI enabled care pathway platform, helps providers identify and reduce under treatment in cardiovascular disease by adding an intelligent layer onto their routinely generated EHR data.
|
|
Heartflow Roadmap Analysis For Efficient Care
As Coronary CT scan volumes increase, your entire reading team needs to deliver efficient and consistent reads. Good thing Heartflow’s Roadmap Analysis can help you maintain accuracy and increase CCTA read speeds by up to 25%, with even level 3 readers seeing real efficiency benefits.
|
|
- The Hidden Costs of Delaying Cardiac MRI Adoption: Despite being the gold standard for functional cardiac imaging, many hospitals remain slow to adopt it. From missed revenue to lost patients, the impact goes far beyond the scan. Read about the real clinical and financial risks of falling behind.
- Monebo’s Customers Lead the Way: Monebo’s customers span across the globe, and range from local cardiac monitoring companies to major ECG OEMs. See what they all have in common, and how the Monebo monitoring advantage might help your business.
- Merge Hemo Expands to Puerto Rico: Merge partnered with Alpha Biomedical to bring Merge Hemo to Puerto Rico, marking the software’s first expansion outside the 50 U.S. states. Read more about the work Merge is doing to expand access to its award winning solutions beyond the United States.
- The All in One Cardiac Imaging Solution: Ready for an all-in-one solution that supports all of your MR and CT needs? See how Circle Cardiovascular Imaging’s cvi42 can streamline your core reading and reporting workflows within a single, customizable platform.
- 5,600 Ways to Improve Your Cardiac Ultrasound Workflow: AI-powered measurements can enhance the way you acquire and interpret cardiac ultrasound. Learn how AI-powered ultrasound can help you overcome everyday limitations in echo. Read Siemens Healthineers’ white paper on how its AI software provides 5,600+ automated measurements to help improve workflow efficiency, consistency, and clinical confidence.
- Heartbeats and EP Insights – How GE HealthCare Streamlines Cardiac Care: Are you stuck behind EP reporting backlogs? Take a break and join GE HealthCare for a 15-minute conversation with Dr. Nicholas Skipitaris of Northwell Health on how to simplify reporting, reduce delays and standardize workflows to scale best practices.
|
|
|
|
|
